On the other hand, as indicated in Section 2, the paired expressions of uPAR and some specific cancer driver genes (i.e., MYC and SMAD4) can be utilized to further differentiate drug effects for precise medication to revert cancerous phenotypic change. This evidence concerns the gene SMAD4 and cancer.